Pharma IQ Glossary: Assay Development
Assay Development is a procedure in molecular biology for testing or measuring the activity of a drug or biochemical in an organism or organic sample. A quantitative assay may also measure the amount of a substance in a sample. Bioassays and immunoassays are among the many varieties of specialized biochemical assays. Other assays measure processes such as enzyme activity, antigen capture, stem cell activity, and competitive protein binding.
Four steps to improve the drug development process
November 18 by Pharma IQ
Pharma IQ takes a look at how the drug discovery process can be improved
3D Stem Cell Assays in Space?- An Interview with NASA's Dr Tom Goodwin
November 05 by Gerald ClarkeWhy are NASA using human stem cells to study the chicken pox virus? How could this help astronauts in space? How is the Mars Rover mission helping? And why are the Russians so interested?&...
Implementing an Electronic Laboratory Notebook (ELN) in pre-clinical drug discovery?
August 29 by Sheraz GulThe pre-clinical phase of drug discovery involves many years of research being conducted by multi-disciplinary teams. These teams will generate significant amounts of data which are processed us...
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
April 19 by Pharmaceuticals & Biotechnology EditorThis video presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Card...
Increasing Efficiency in Drug Discovery & Development with Aptuit Medicines Research Centre
September 07 by Andrea CharlesIn this podcast Mark Hembarsky, Vice President and Site Leader of the Aptuit Medicines Research Centre in Verona, Italy, and his colleagues Mauro Corsi, Head of Assay Development and In Vitro Profilin...
3 Ways to Incorporate Adaptive Trials into Your Oncology Drug Development Plans
June 06 by Andrea CharlesThe lengthy clinical development process of drug development for life threatening diseases is not an optimal development strategy for oncology therapeutic area. Adaptive designs have become popular to...
FDA to Address Industry Questions about Biosimilar Regulations at the Pharma's IQ Immunogenicity Event
April 04 by Pharma IQ NewsThis May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's Immunogenicity event to discuss FDA directives on Immu...
Why Changes are needed to Current Preformulation and Formulation Practices
March 15 by Andrea CharlesAs part of the Pharma Leaders Today Series Dr. Keith Horspool, Vice President, Pharmaceutical Development US, Boehringer Ingelheim, speaks to Andrea Charles from Pharma IQ, about why changes are...
Assay Development and Immunogenicity Testing
February 25 by Pharma IQImmunogenicity is becoming an integral feature within drug development activities. Testing immunogenicity, however, presents those within the pharmaceutical industry with a host of challenges; ones w...
Success and Accuracy in Genotoxicity and Carcinogenicity Testing: An FDA Perspective
September 21 by Pharma IQDr. Timothy Robison, Pharmacology/Toxicology Reviewer at the US Food and Drug Administration/CDER, joins Helen Winsor from Pharma IQ, to share the latest insights into achieving successful characteris...
Improving Biomarker Development Work Flow in Phase I Clinical Development
September 07 by Helen WinsorReto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best...
Streamlining the Development and Validation Process in Discovery to Phase I Clinical Development
September 05 by Pharma IQReto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker de...
